ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in Phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone858-558-2871
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$223.81 million
Profitability
Miscellaneous
Employees465
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions
What is ACADIA Pharmaceuticals' stock symbol?
ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."
How were ACADIA Pharmaceuticals' earnings last quarter?
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) posted its quarterly earnings data on Wednesday, July, 31st. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.46) by $0.08. The biopharmaceutical company had revenue of $83.21 million for the quarter, compared to analysts' expectations of $72.50 million. ACADIA Pharmaceuticals had a negative net margin of 101.45% and a negative return on equity of 70.97%. The business's revenue was up 45.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.51) earnings per share. View ACADIA Pharmaceuticals' Earnings History.
When is ACADIA Pharmaceuticals' next earnings date?
What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?
ACADIA Pharmaceuticals issued an update on its FY 2019 earnings guidance on Wednesday, July, 31st. The company provided EPS guidance of for the period. The company issued revenue guidance of $320-330 million, compared to the consensus revenue estimate of $292.81 million.
What price target have analysts set for ACAD?
14 Wall Street analysts have issued 1 year price objectives for ACADIA Pharmaceuticals' stock. Their predictions range from $31.00 to $66.00. On average, they anticipate ACADIA Pharmaceuticals' stock price to reach $49.43 in the next year. This suggests a possible upside of 23.7% from the stock's current price. View Analyst Price Targets for ACADIA Pharmaceuticals.
What is the consensus analysts' recommendation for ACADIA Pharmaceuticals?
14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 2 hold ratings, 11 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ACADIA Pharmaceuticals.
What are Wall Street analysts saying about ACADIA Pharmaceuticals stock?
Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (9/11/2019)
- 2. HC Wainwright analysts commented, "Our $60 PT is based on an equally weighted composite of: (a) $71.86/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $3.50 discounted back to and (b) an NPV of $47.36/share (discount rate 10%, growth rate 2%). Risks to our investment thesis and target price include: (1) failure of Nuplazid in further clinical studies; (2) failure of Nuplazid to secure regulatory approval in further indications; and (3) failure of Nuplazid to achieve peak commercial revenue estimates in our model, due to market size, penetration rates, and pricing." (5/3/2019)
- 3. JPMorgan Chase & Co. analysts commented, "Dexcom posted another sizable sales beat, besting consensus expectation by almost $35M, and raised 2019 revenue guidance by $75M. The familiar topics of pricing and competition ruled much of the discussion, but there was little new on either front, in our view. Some revenue is expected to go toward higher operating expenses as the company invests in new markets, the Verily product, and G6 line extensions. We remain concerned that pricing pressures could arise—perhaps suddenly—but also may not occur for years. We frankly haven’t figured out what work to do to predict when or if insurers may push on price due to competition pricing lower. We remain Neutral as we feel we have no way to eliminate or estimate this risk but do believe DXCM shares will move higher should pricing fears not play out. CGM is good medicine and should be used by all MDI diabetics, in our view." (5/2/2019)
- 4. Cantor Fitzgerald analysts commented, "We are OW on ACAD with a 12-month PT of $30 based on NUPLAZID/pimavanserin in PDP/other neuropsych indications. NUPLAZID remains the only agent approved for PDP against a class of atypical antipsych drugs used off-label. In our view, new patient/revs growth should resume as an awareness campaign gains traction. We see increasingly visible broadening clinical evaluation of pima’ in DRP (and other psych indications) as fueling LT growth, and believe the PoS for these studies is underappreciated at current trading levels. Valuation Summary In valuing ACAD, we used a discounted NPV revenue calculation." (4/25/2019)
Has ACADIA Pharmaceuticals been receiving favorable news coverage?
News stories about ACAD stock have trended somewhat negative this week, InfoTrie Sentiment reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ACADIA Pharmaceuticals earned a news impact score of -1.9 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for ACADIA Pharmaceuticals.
Who are some of ACADIA Pharmaceuticals' key competitors?
Some companies that are related to ACADIA Pharmaceuticals include Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), UCB (UCBJF), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Elanco Animal Health (ELAN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), GALAPAGOS NV/S (GLPG), Bausch Health Companies (BHC) and Teva Pharmaceutical Industries (TEVA).
What other stocks do shareholders of ACADIA Pharmaceuticals own?
Who are ACADIA Pharmaceuticals' key executives?
ACADIA Pharmaceuticals' management team includes the folowing people:
- Mr. Stephen R. Davis, CEO & Director (Age 58)
- Dr. Srdjan R. Stankovic, Pres (Age 62)
- Mr. Michael J. Yang, Exec. VP & Chief Commercial Officer (Age 57)
- Ms. Elena H. Ridloff C.F.A., CFA, Exec. VP & CFO (Age 39)
- Mr. Eric Alejandro Miller, Controller & Principal Accounting Officer (Age 40)
Who are ACADIA Pharmaceuticals' major shareholders?
ACADIA Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Peregrine Capital Management LLC (0.27%), First Midwest Bank Trust Division (0.02%), Assenagon Asset Management S.A. (0.01%), Campbell & CO Investment Adviser LLC (0.01%), Fox Run Management L.L.C. (0.01%) and Envestnet Asset Management Inc. (0.01%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Daniel B Soland, Eric Alejandro Miller, Glenn Baity, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis. View Institutional Ownership Trends for ACADIA Pharmaceuticals.
Which institutional investors are selling ACADIA Pharmaceuticals stock?
ACAD stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and First Midwest Bank Trust Division. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Eric Alejandro Miller, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic and Stephen Davis. View Insider Buying and Selling for ACADIA Pharmaceuticals.
Which institutional investors are buying ACADIA Pharmaceuticals stock?
ACAD stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Campbell & CO Investment Adviser LLC, Fox Run Management L.L.C., Envestnet Asset Management Inc., Meeder Asset Management Inc. and North Star Investment Management Corp.. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and Daniel B Soland. View Insider Buying and Selling for ACADIA Pharmaceuticals.
How do I buy shares of ACADIA Pharmaceuticals?
Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is ACADIA Pharmaceuticals' stock price today?
One share of ACAD stock can currently be purchased for approximately $39.95.
How big of a company is ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals has a market capitalization of $5.77 billion and generates $223.81 million in revenue each year. The biopharmaceutical company earns $-245,190,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. ACADIA Pharmaceuticals employs 465 workers across the globe.View Additional Information About ACADIA Pharmaceuticals.
What is ACADIA Pharmaceuticals' official website?
How can I contact ACADIA Pharmaceuticals?
ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]
MarketBeat Community Rating for ACADIA Pharmaceuticals (NASDAQ ACAD)
MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
